NVCR - NovoCure Ltd

QQQ $ 435.98 $ 8.58 (2.01 %)

DIA $ 386.87 $ 4.54 (1.19 %)

SPY $ 511.25 $ 6.26 (1.24 %)

TLT $ 89.88 $ 0.90 (1.01 %)

GLD $ 212.97 $ -0.17 (-0.08 %)

Previous Close

$ 14.78

Open

$ 14.57

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 14.32 - $ 15.42

52 Week Range

$ 10.87 - $ 83.60

Volume

1,145,704

Average Volume

Market Cap

1.59B

Beta (5Y Monthly)

$ 1.29

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-02-2024	03-31-2024	10-Q
2	02-22-2024	12-31-2023	10-K
3	10-26-2023	09-30-2023	10-Q
4	07-27-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	02-23-2023	12-31-2022	10-K
7	10-27-2022	09-30-2022	10-Q
8	07-28-2022	06-30-2022	10-Q
9	04-28-2022	03-31-2022	10-Q
10	02-24-2022	12-31-2021	10-K
11	10-28-2021	09-30-2021	10-Q
12	07-29-2021	06-30-2021	10-Q
13	04-29-2021	03-31-2021	10-Q
14	02-25-2021	12-31-2020	10-K
15	10-29-2020	09-30-2020	10-Q
16	07-30-2020	06-30-2020	10-Q
17	04-30-2020	03-31-2020	10-Q
18	02-27-2020	12-31-2019	10-K
19	10-31-2019	09-30-2019	10-Q
20	07-25-2019	06-30-2019	10-Q
21	05-02-2019	03-31-2019	10-Q
22	02-28-2019	12-31-2018	10-K
23	10-25-2018	09-30-2018	10-Q
24	07-26-2018	06-30-2018	10-Q
25	04-26-2018	03-31-2018	10-Q
26	02-22-2018	12-31-2017	10-K
27	10-26-2017	09-30-2017	10-Q
28	07-27-2017	06-30-2017	10-Q
29	04-27-2017	03-31-2017	10-Q
30	02-23-2017	12-31-2016	10-K
31	11-02-2016	09-30-2016	10-Q
32	07-28-2016	06-30-2016	10-Q
33	05-10-2016	03-31-2016	10-Q
34	03-01-2016	12-31-2015	10-K
35	10-27-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Unveiling 8 Analyst Insights On NovoCure
05/02/2024 21:01:09

HC Wainwright & Co. Maintains Neutral on N...
05/02/2024 16:41:26

HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Neutral and lowers the price target fro...

Novocure Secures $400M Multi-Tranche Non-D...
05/02/2024 11:37:19

Novocure Secures New $400M Non-Dilutive De...
05/02/2024 11:18:50

Use of proceeds to fund working capital needs stemming from Novocure's anticipated launch in non-small cell lung cancer and...

NovoCure Q1 2024 Adj EPS $(0.36) Beats $(0...
05/02/2024 11:04:47

NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.42) by 1...

Results Of Novocure's METIS Phase 3 Clinic...
04/24/2024 14:46:57

Novocure (NASDAQ:NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell ...

Piper Sandler Reiterates Overweight on Nov...
04/10/2024 12:55:11

Piper Sandler analyst Jason Bednar reiterates NovoCure (NASDAQ:NVCR) with a Overweight and raises the price target from $25 ...

Novocure Reports 20 Presentations On Tumor...
04/05/2024 11:01:17

10-health-care-stocks-whale-activity-in-todays-session

10 Health Care Stocks Whale Activity In To...
04/03/2024 17:35:24

Wells Fargo Maintains Overweight on NovoCu...
04/03/2024 16:43:45

Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Overweight and lowers the price target from $49 ...

Peeling Back The Layers: Exploring NovoCur...
03/27/2024 20:01:01

HC Wainwright & Co. Maintains Neutral on N...
03/27/2024 17:44:29

HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target fro...

novocure-stock-soars-its-lung-cancer-electric-field-treatment-slows-progression-to-brain-data-shows

Novocure Stock Soars, Its Lung Cancer Elec...
03/27/2024 14:16:57

Novocure's Phase 3 METIS trial results: TTFields therapy, combined with supportive care, significantly prolongs time to int...

Cintas Reports Upbeat Earnings, Joins PayS...
03/27/2024 14:03:27

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.

NovoCure Shares Halted On Circuit Breaker ...
03/27/2024 13:37:49

Novocure Announces METIS Phase 3 Clinical ...
03/27/2024 13:30:21

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Field...

12-health-care-stocks-moving-in-wednesdays-pre-market-session

12 Health Care Stocks Moving In Wednesday'...
03/27/2024 13:05:57

Market-Moving News for March 27th
03/27/2024 12:31:22

IBIO: 119% | IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for ob...

Novocure's METIS Phase 3 Trial Met Primary...
03/27/2024 11:09:25

HC Wainwright & Co. Reiterates Neutral on ...
03/12/2024 14:23:43

HC Wainwright & Co. analyst Emily Bodnar reiterates NovoCure (NASDAQ:NVCR) with a Neutral and maintains $22 price target.